GLP-1 Drugs May Extend Colon Cancer Patients' Lives

According to a study published on November 11, 2025, colon cancer patients who take GLP-1 drugs like Ozempic and Wegovy may have a significantly better chance of survival. Researchers at UC San Diego analyzed data from over 6,800 colon cancer patients and found that those taking these popular diabetes and weight-loss medications were much less likely to die within 5 years compared to non-users.

The study revealed that only around 15% of GLP-1 drug users passed away within 5 years, in contrast to 37% of those not taking the medications. This survival benefit persisted even after accounting for factors like age, cancer severity, and other medical conditions. The researchers noted that the positive impact was most pronounced in patients with severe obesity, defined as a BMI of 35 or higher.

Experts believe the GLP-1 drugs' ability to reduce inflammation, lower insulin levels, and promote weight loss could be the key reasons behind the improved cancer outcomes. Some scientists also suspect these medications may have a direct effect on tumor cells, though this has not yet been conclusively proven.

While the findings are promising, the researchers caution that this was an observational study and cannot definitively prove that GLP-1 drugs caused the extended survival. They emphasize the need for more research, including randomized trials, to confirm these results and better understand the mechanisms involved.